Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Mechanism Behind Chronic Fibrosis Discovered
Disease Discoveries

Mechanism Behind Chronic Fibrosis Discovered

By Nora DunneJun 13, 2016
Share
Facebook Twitter Email
skin biopsy-tenascin-C
An image using immunofluorescence microscopy shows a scleroderma skin biopsy stained with antibodies 
to tenascin-C.

Scarring, or fibrosis, is normally a temporary part of the wound healing process. But in fibrotic diseases, the body fails to stop producing the thick and hard connective tissue that repairs skin and other organs after injury. In a recent study published in Nature Communications, Northwestern Medicine scientists discovered that a molecule called tenascin-C is responsible for driving that excess scar buildup.

The scientists focused on scleroderma, a rare autoimmune disorder also called systemic sclerosis that is characterized by progressive fibrosis in the skin and lungs. This study’s findings could inform future therapies for scleroderma as well as other fibrotic diseases, which can lead to serious organ damage and even death. Currently, there are no effective treatments to slow, stop or reverse the progression of fibrosis.

“If you have an injury in your liver from a virus or in the lungs from an infection, you might get limited and transient scarring, but that scarring resolves itself and the tissue regenerates,” said principal investigator John Varga, MD, John and Nancy Hughes Distinguished Professor of Rheumatology and of Dermatology. “When excessive tenascin-C is present, this repair doesn’t seem to happen.”

During fetal development, tenascin-C is expressed in the connective tissues that form the scaffolds for the body’s organs.

Varga_John_2501
John Varga, MD, John and Nancy Hughes Distinguished Professor of Rheumatology and of Dermatology, was principal investigator of a study that discovered a molecule responsible for driving the excess scar buildup seen in fibrotic diseases.

“In adults, this molecule has only a limited role,” Varga said. “But somehow it starts being made again in chronic fibrosis.”

In the study, he and first author Swati Bhattacharyya, PhD, ’05 GME, research associate professor of Medicine in the Division of Rheumatology, determined that levels of tenascin-C were markedly elevated in skin and lung samples from patients with scleroderma, suggesting that the molecule might be a biomarker of the disease.

“We looked at several independent patient cohorts to validate the findings,” Varga said. “Could we measure tenascin-C and use it to inform decisions about treatment?”

The research team also studied the disease in animal models without the tenascin-C gene. They discovered that mice lacking the molecule did not develop chronic fibrosis. The scientists then investigated ways to pharmacologically inhibit tenascin-C, because it is not possible to delete the gene in humans.

“We asked: How does the cell respond to this molecule? What is the sensor that tells the cell that there’s too much tenascin-c?” Varga explained. “We discovered that the sensor is the well-known immunoreceptor toll-like receptor 4, which is really exciting, because we have inhibitors that can block this receptor.”

In ongoing research, Varga’s lab is exploring novel compounds that can safely be given to patients to stop toll-like receptor 4 from responding to tenascin-c and driving fibrosis. The investigators are also collaborating with cardiologists and neurologists to see how tenascin-c is involved in repair after heart attacks and spinal cord injuries.

“This is potentially a very generalizable mechanism that may account for fibrosis and damage in many diseases in different organs,” Varga said.

This study was supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases grants AR-42309 and K24 AR060297.

Varga was also recently elected to the Henry Kunkel Society, an association of distinguished clinical investigators primarily in the field of immunology.

Allergy & Immunology Dermatology Research
Share. Facebook Twitter Email

Related Posts

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Calcium Channel Blockers May Improve Chemotherapy Response

Jun 21, 2022

Comments are closed.

Latest News

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022

Calcium Channel Blockers May Improve Chemotherapy Response

Jun 21, 2022

Expanded Role for Calcium Channels in T-Cells

Jun 17, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220607_Feinberg Campus_0070
20220607_Feinberg Campus_0066
20220607_Feinberg Campus_0054
Northwestern University 2022. Photo by Jim Prisching
20220607_Feinberg Campus_0077
20220607_Feinberg Campus_0063
20220607_Feinberg Campus_0111
20220607_Feinberg Campus_0083
20220607_Feinberg Campus_0018
20220607_Feinberg Campus_0023
20220607_Feinberg Campus_0072 (2)
20220607_Feinberg Campus_0120

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.